http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2374248-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c26895e1df2ffdb5a7a07dc40911694c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-00 |
| filingDate | 1999-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_162c1c76fbe8f1431946ccc0854cc614 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_184700b75debe074b60266d52d958c0c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5eb2bdb5102dea9b4d7769c6342637fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9422384c933f495b877e4fe3851eebc2 |
| publicationDate | 1999-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2374248-A1 |
| titleOfInvention | Gene therapy vectors and their use in antitumour therapy |
| abstract | Vector material useful for antitumour therapy contains: (a) a tumour cell sensitizing gene or genes of which expression in a tumour cell yields a sensitizing gene expression product having a potential to cause tumour cells to be killed and destroyed, or to be eliminated, or otherwise to be inactivated, or to be rendered sensitive and/or vulnerable to destruction; ( b) a sensitizing gene promoter; (c) at least one control gene; and (d) a contro l gene expression regulatory system responsive in use in a transfected cell to the effect of a predetermined exogenous or endogenous expression inducing influence, e.g. ionizing radiation, heat or a chemical inducing agent, so as to induce expression of the control gene to yield an expression product havi ng a capacity to establish an operative linkage between the sensitizing gene promoter and the sensitizing gene or genes effective to trigger and switch o n or permit continuous or permanent expression of the latter to bring about continuous production of the sensitizing gene expression product. This is preferably achieved by arranging for the control gene to encode a recombinas e enzyme that acts on recombinase target sites in a Cre-loxP or Flp-frt site specific recombination system to remove an expression preventing stop casset te sequence between the sensitizing gene(s) and the promoter for the latter. In some embodiments the tumour sensitizing gene expression product will be an enzyme or other bioactive agent that can activate an inactive prodrug.</SDOA B> |
| priorityDate | 1998-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1026.